Fig. 2.

Effect of DPP4i on liver-to-body weight ratio and NAFLD activity score in a mouse model of nonalcoholic steatohepatitis-related hepatocellular carcinoma. a Liver-to-body weight ratio at 18 weeks of age in the DPP4i group (red; n = 8) and in the control group (black; n = 8). b Microscopic images for hematoxylin-eosin staining of the liver in the DPP4i group and in the control group. Upper row: low magnification. Lower row: high magnification. c NAFLD activity score in the DPP4i group (n = 8) and in the control group (n = 8). Statistical differences between the DPP4i group and the control group were analyzed by the Wilcoxon rank-sum test. p values of < 0.05 were considered significant. DPP4i, dipeptidyl peptidase-4 inhibitor; NAFLD, nonalcoholic fatty liver disease.